{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:31:10Z","timestamp":1759602670820},"reference-count":35,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.3892\/or.2014.3563","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T12:41:32Z","timestamp":1413981692000},"page":"111-118","source":"Crossref","is-referenced-by-count":6,"title":["Potent antitumor activity of the Ad5\/11 chimeric oncolytic adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis"],"prefix":"10.3892","volume":"33","author":[{"given":"XUBIN","family":"WEI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LI","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GANG","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEI","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KE","family":"XU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HONGYAN","family":"QI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HONG","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JING","family":"SHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHONGJIE","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIMIN","family":"SHAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,10,22]]},"reference":[{"key":"key20180107213534_b1-or-33-01-0111","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"key20180107213534_b2-or-33-01-0111","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1200\/JCO.2005.05.010","article-title":"Genetics of myeloid malignancies: pathogenetic and clinical implications","volume":"23","author":"Frohling","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107213534_b3-or-33-01-0111","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"key20180107213534_b4-or-33-01-0111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0959-437X(02)00018-7","article-title":"The core-binding factor leukemias: lessons learned from murine models","volume":"13","author":"Downing","year":"2003","journal-title":"Curr Opin Genet Dev"},{"key":"key20180107213534_b5-or-33-01-0111","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1053\/j.seminoncol.2008.04.004","article-title":"Deregulation of signaling pathways in acute myeloid leukemia","volume":"35","author":"Scholl","year":"2008","journal-title":"Semin Oncol"},{"key":"key20180107213534_b6-or-33-01-0111","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2006-02-003475","article-title":"Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia","volume":"108","author":"Kornblau","year":"2006","journal-title":"Blood"},{"key":"key20180107213534_b7-or-33-01-0111","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"key20180107213534_b8-or-33-01-0111","first-page":"561","article-title":"Gene therapy for liver cancer: clinical experience and future prospects","volume":"12","author":"Sangro","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"key20180107213534_b9-or-33-01-0111","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-61779-095-9_2","article-title":"Introduction to gene therapy: a clinical aftermath","volume":"737","author":"Denefle","year":"2011","journal-title":"Methods Mol Biol"},{"key":"key20180107213534_b10-or-33-01-0111","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev.med.53.082901.104039","article-title":"Cancer gene therapy: scientific basis","volume":"53","author":"Wadhwa","year":"2002","journal-title":"Annu Rev Med"},{"key":"key20180107213534_b11-or-33-01-0111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.genom.2.1.177","article-title":"Gene therapy: promises and problems","volume":"2","author":"Pfeifer","year":"2001","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"key20180107213534_b12-or-33-01-0111","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/gast.2002.35132","article-title":"New strategies to enhance gene therapy efficiency","volume":"123","author":"Qian","year":"2002","journal-title":"Gastroenterology"},{"key":"key20180107213534_b13-or-33-01-0111","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/v2010078","article-title":"Oncolytic viruses for cancer therapy: overcoming the obstacles","volume":"2","author":"Wong","year":"2010","journal-title":"Viruses"},{"key":"key20180107213534_b14-or-33-01-0111","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/sj.cr.7310025","article-title":"Therapy of cancer by cytokines mediated by gene therapy approach","volume":"16","author":"Qian","year":"2006","journal-title":"Cell Res"},{"key":"key20180107213534_b15-or-33-01-0111","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/89901","article-title":"Replication-selective virotherapy for cancer: biological principles, risk management and future directions","volume":"7","author":"Kirn","year":"2001","journal-title":"Nat Med"},{"key":"key20180107213534_b16-or-33-01-0111","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/156652308786848067","article-title":"Applications of lentiviral vectors for shRNA delivery and transgenesis","volume":"8","author":"Singer","year":"2008","journal-title":"Curr Gene Ther"},{"key":"key20180107213534_b17-or-33-01-0111","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1038\/sj.onc.1209040","article-title":"Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus","volume":"24","author":"Berk","year":"2005","journal-title":"Oncogene"},{"key":"key20180107213534_b18-or-33-01-0111","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.4161\/cbt.6.11.4831","article-title":"The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma","volume":"6","author":"Zhang","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"key20180107213534_b19-or-33-01-0111","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","article-title":"The RB and p53 pathways in cancer","volume":"2","author":"Sherr","year":"2002","journal-title":"Cancer Cell"},{"key":"key20180107213534_b20-or-33-01-0111","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/hep.21951","article-title":"Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma","volume":"47","author":"Cui","year":"2008","journal-title":"Hepatology"},{"key":"key20180107213534_b21-or-33-01-0111","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1566523044578077","article-title":"Promoters and control elements: designing expression cassettes for gene therapy","volume":"4","author":"Papadakis","year":"2004","journal-title":"Curr Gene Ther"},{"key":"key20180107213534_b22-or-33-01-0111","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-07-4596","article-title":"Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7\/IL-24 gene","volume":"14","author":"Luo","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20180107213534_b23-or-33-01-0111","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1128\/JVI.74.3.1457-1467.2000","article-title":"Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines","volume":"74","author":"Segerman","year":"2000","journal-title":"J Virol"},{"key":"key20180107213534_b24-or-33-01-0111","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2006.01.003","article-title":"Adenovirus type 5 interactions with human blood cells may compromise systemic delivery","volume":"14","author":"Lyons","year":"2006","journal-title":"Mol Ther"},{"key":"key20180107213534_b25-or-33-01-0111","first-page":"2311","article-title":"Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners","volume":"27","author":"Yu","year":"2007","journal-title":"Anticancer Res"},{"key":"key20180107213534_b26-or-33-01-0111","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1146\/annurev.immunol.22.012703.104622","article-title":"Interleukin-10 and related cytokines and receptors","volume":"22","author":"Pestka","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"key20180107213534_b27-or-33-01-0111","first-page":"985","article-title":"mda-7\/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review)","volume":"31","author":"Lebedeva","year":"2007","journal-title":"Int J Oncol"},{"key":"key20180107213534_b28-or-33-01-0111","doi-asserted-by":"crossref","first-page":"10128","DOI":"10.1158\/0008-5472.CAN-05-3127","article-title":"Is mda-7\/IL-24 a \u2018magic bullet\u2019 for cancer?","volume":"65","author":"Fisher","year":"2005","journal-title":"Cancer Res"},{"key":"key20180107213534_b29-or-33-01-0111","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1359-6101(02)00074-6","article-title":"MDA-7\/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine","volume":"14","author":"Sauane","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20180107213534_b30-or-33-01-0111","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.leu.2405034","article-title":"Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7\/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis","volume":"22","author":"Qian","year":"2008","journal-title":"Leukemia"},{"key":"key20180107213534_b31-or-33-01-0111","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.cgt.7700969","article-title":"The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer","volume":"13","author":"Zhao","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"key20180107213534_b32-or-33-01-0111","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1038\/sj.onc.1209037","article-title":"Oncolytic viral therapies - the clinical experience","volume":"24","author":"Aghi","year":"2005","journal-title":"Oncogene"},{"key":"key20180107213534_b33-or-33-01-0111","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1038\/sj.onc.1209044","article-title":"Oncolytic adeno-viruses - selective retargeting to tumor cells","volume":"24","author":"Mathis","year":"2005","journal-title":"Oncogene"},{"key":"key20180107213534_b34-or-33-01-0111","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/mt.2011.242","article-title":"Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11","volume":"20","author":"Wong","year":"2012","journal-title":"Mol Ther"},{"key":"key20180107213534_b35-or-33-01-0111","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.1128\/JVI.77.17.9183-9191.2003","article-title":"Adenovirus type 11 uses CD46 as a cellular receptor","volume":"77","author":"Segerman","year":"2003","journal-title":"J Virol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2014.3563\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T21:36:16Z","timestamp":1515360976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2014.3563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,10,22]]},"published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.3892\/or.2014.3563"],"URL":"https:\/\/doi.org\/10.3892\/or.2014.3563","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,22]]}}}